New advances of pemetrexed (Alimta~) in the treatment of non-small-cell lung cancer
- VernacularTitle:培美曲塞(Alimta~)治疗非小细胞肺癌新进展
- Author:
Yilong WU
;
Scagliotti GIORGIO
- Publication Type:Journal Article
- Keywords:
non-small-cell lung cancer;
pemetrexed;
chemotherapy
- From:
China Oncology
2006;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Pemetrexed is an antimetabolite antineoplastic agent that exerts its action by inhibiting three enzymes-thymidylate synthetase (TS), glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), which are essential for the synthesis of purine and pyrimidine. It causes arrest of tumor cells in S phase of the cell cycle, thus inhibiting their growth.Pemetrexed has been approved as first-line treatment in malignant pleural mesothelioma and second-line treatment in non-small-cell lung cancer (NSCLC). This paper summarizes the current developments in the treatment of NSCLC.
